LOS ANGELES, March 4, 2015 Tauriga Sciences, Inc. (OTCQB:
TAUG) ("Tauriga" or the "Company"), a diversified life sciences
company with interests in the natural wellness sector and in
developing a proprietary synthetic biology platform technology,
announced today that it has expanded its July, 2014
non-exclusive licensing agreement with Targeted Medical Pharma Inc.
(OTCQB: TRGM) ("Targeted Medical"). The agreement involves
two products in Tauriga's current natural wellness line that
Tauriga has reformulated and relabeled as dietary supplements from
Targeted Medical's medical food formulations: ClearNaze, a natural
decongestant without stimulant or drowsiness effects, and
Satietiva, an amino acid-based appetite suppressant. Tauriga
and Targeted Medical expanded the original July, 2014 non-exclusive
licensing agreement to allow Tauriga to market and sell directly to
all consumers, not just to those with an interest in the effects of
medicinal cannabis.
Tauriga Chairman and CEO Dr. Stella M.
Sung states, "We are thrilled to commercialize ClearNaze and
Satietiva, along with Tauriga's proprietary formulations, to a
broader population because we believe that all of our natural
wellness products produce functional improvement independent of the
etiology or cause of the health challenge."
Targeted Medical CEO Kim Giffoni
adds, "The expanded relationship is beneficial for both
companies. Tauriga's success in generating revenues for
ClearNaze and Satietiva will result in royalty revenue for Targeted
Medical, and our efforts are complementary and synergistic."
Tauriga's recently launched natural wellness product line
currently consists of six products. Two of these products
contain cannabidiol (CBD) oil extracted from non-GMO industrial
hemp as their key ingredient: CannaCaviar, the Company's
cannabidiol (CBD) soft gels; and TopiCanna, Tauriga's proprietary
topical medicinal cannabis cream. Both TopiCanna and
CannaCaviar are designed to provide potential natural wellness and
healing properties without psychoactive effects. Tauriga has
two non-cannabis containing natural wellness dietary supplements in
addition to ClearNaze and Satietiva: IndiCalm, an anxiolytic
that does not induce cognitive impairment, and MendOCan, a highly
pure, potent and palatable Omega 3 supplement. For more
information on Tauriga's natural wellness product line, please
visit www.taurigastore.com.
Lawrence A. May, M.D., Tauriga's
Chief Medical Officer and previously head of medical affairs at
Herbalife, states, "I have worked with medical foods for over ten
years, and I am enthusiastic about applying the technology for
generating neurotransmitters to create dietary supplements that
improve function and enhance health. Until now, this
technology was only available under physician supervision.
Tauriga's products provide the consumer direct access to the
technology for the first time."
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc.
(TAUG) is a diversified life sciences company focused on generating
profitable revenues in the natural wellness sector and in
developing a proprietary synthetic biology platform
technology. The mission of the Company is to acquire and
build a diversified portfolio of cutting edge technology assets
that is capital efficient and of significant value to the
shareholders. The Company's business model includes the acquisition
of licenses, equity stakes, rights on both an exclusive and
non-exclusive basis, and entire businesses. Management is firmly
committed to building lasting shareholder value in the short,
intermediate, and long terms. Please visit the Company's
corporate website at www.tauriga.com and the Company's e-commerce
website at www.taurigastore.com.
NON SOLICITATION:
This press release does not
constitute an offer to sell or the solicitation of an offer to buy
any of these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale is not permitted. Any securities offered or
issued in connection with the above-referenced merger and/or
investment have not been registered, and will be offered pursuant
to an exemption from registration.
DISCLAIMER:
Forward-Looking Statements: Except for
statements of historical fact, this news release contains certain
"forward-looking statements" as defined by the Private Securities
Litigation Reform Act of 1995, including, without limitation
expectations, beliefs, plans and objectives regarding the
development, use and marketability of products. Such
forward-looking statements are based on present circumstances and
on TAUG's predictions with respect to events that have not
occurred, that may not occur, or that may occur with different
consequences and timing than those now assumed or anticipated. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors, and are not guarantees of future
performance or results and involve risks and uncertainties that
could cause actual events or results to differ materially from the
events or results expressed or implied by such forward-looking
statements. Such factors include general economic and business
conditions, the ability to successfully develop and market
products, consumer and business consumption habits, the ability to
fund operations and other factors over which TAUG has little or no
control. Such forward-looking statements are made only as of the
date of this release, and TAUG assumes no obligation to update
forward-looking statements to reflect subsequent events or
circumstances. Readers should not place undue reliance on these
forward-looking statements. Risks, uncertainties and other factors
are discussed in documents filed from time to time by TAUG with the
Securities and Exchange Commission. This press release does not and
shall not constitute an offer to sell or the solicitation of any
offer to buy any of the securities, nor shall there be any sale of
the securities, in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state. The
securities have not been registered under the Securities Act of
1933, as amended (the "Securities Act") or any state securities
laws, and may not be offered or sold in the United States absent registration, or an
applicable exemption from registration, under the Securities Act
and applicable state securities laws.
Food and Drug Administration Disclaimer: None of the
statements contained in this press release regarding any of the
products either offered or to be offered in the future by the
Company have been evaluated by the Food and Drug
Administration. Additionally, none of the products is
intended to diagnose, treat, cure, or prevent any disease.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/tauriga-sciences-inc-expands-agreement-with-targeted-medical-pharma-inc-300045217.html
SOURCE Tauriga Sciences, Inc.
